Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928566 | 1.00 | KCNH2 (0.63) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL51073 | 0.93 | KCNH2 (0.63) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936789 | 0.93 | KCNH2 (0.63) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936937 | 0.93 | KCNH2 (0.63) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14438778 | 0.92 | KCNH2 (0.68) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14393137 | 0.92 | KCNH2 (0.68) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14438784 | 0.92 | KCNH2 (0.68) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL825186 | 0.92 | KCNH2 (0.66) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL825337 | 0.90 | KCNH2 (0.59) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14088788 | 0.90 | NR1I2 (0.66) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485633-B2 | RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| US-7399758-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-15 | — | — | US | disclosed |
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | KCNH2 934/4885NR1I2 201/4885CYP3A4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.